Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency
Z Li, X Lai, S Fu, L Ren, H Cai, H Zhang, Z Gu… - Advanced …, 2022 - Wiley Online Library
Tumor immunotherapy is only effective in a fraction of patients due to a low response rate
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …
Immunogenic cell death in cancer therapy: Present and emerging inducers
J Zhou, G Wang, Y Chen, H Wang… - Journal of cellular and …, 2019 - Wiley Online Library
In the tumour microenvironment (TME), immunogenic cell death (ICD) plays a major role in
stimulating the dysfunctional antitumour immune system. Chronic exposure of damage …
stimulating the dysfunctional antitumour immune system. Chronic exposure of damage …
Fibronectin-coated metal–phenolic networks for cooperative tumor chemo-/chemodynamic/immune therapy via enhanced ferroptosis-mediated immunogenic cell …
Y Xu, Y Guo, C Zhang, M Zhan, L Jia, S Song, C Jiang… - Acs Nano, 2022 - ACS Publications
The development of nanomedicine formulations to overcome the disadvantages of
traditional chemotherapeutic drugs and integrate cooperative theranostic modes still …
traditional chemotherapeutic drugs and integrate cooperative theranostic modes still …
Massively evoking immunogenic cell death by focused mitochondrial oxidative stress using an AIE luminogen with a twisted molecular structure
Immunogenic cell death (ICD) provides momentous theoretical principle for modern cancer
immunotherapy. However, the currently available ICD inducers are still very limited and …
immunotherapy. However, the currently available ICD inducers are still very limited and …
Nanoparticle‐mediated immunogenic cell death enables and potentiates cancer immunotherapy
Cancer immunotherapies that train or stimulate the inherent immunological systems to
recognize, attack, and eradicate tumor cells with minimal damage to healthy cells have …
recognize, attack, and eradicate tumor cells with minimal damage to healthy cells have …
Tumor targeting via EPR: Strategies to enhance patient responses
The tumor accumulation of nanomedicines relies on the enhanced permeability and
retention (EPR) effect. In the last 5–10 years, it has been increasingly recognized that there …
retention (EPR) effect. In the last 5–10 years, it has been increasingly recognized that there …
Nanotechnology for multimodal synergistic cancer therapy
The complexity, diversity, and heterogeneity of tumors seriously undermine the therapeutic
potential of treatment. Therefore, the current trend in clinical research has gradually shifted …
potential of treatment. Therefore, the current trend in clinical research has gradually shifted …
Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition
Natural, extracellular membrane vesicles secreted by Gram-negative bacteria, outer
membrane vesicles (OMVs), contain numerous pathogen-associated molecular patterns …
membrane vesicles (OMVs), contain numerous pathogen-associated molecular patterns …
Combining nanomedicine and immunotherapy
Conspectus Nanomedicine holds significant potential to improve the efficacy of cancer
immunotherapy. Thus far, nanomedicines, ie, 1–100 (0) nm sized drug delivery systems …
immunotherapy. Thus far, nanomedicines, ie, 1–100 (0) nm sized drug delivery systems …
PLGA-based nanoparticles in cancer treatment
S Rezvantalab, NI Drude, MK Moraveji… - Frontiers in …, 2018 - frontiersin.org
Nanomedicines can be used for a variety of cancer therapies including tumor-targeted drug
delivery, hyperthermia, and photodynamic therapy. Poly (lactic-co-glycolic acid)(PLGA) …
delivery, hyperthermia, and photodynamic therapy. Poly (lactic-co-glycolic acid)(PLGA) …